Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

Core Viewpoint - Lowey Dannenberg P.C. is investigating Fulgent Genetics, Inc. for potential violations of federal securities laws following the company's financial results for 2025, which fell short of expectations [1][2]. Financial Performance - Fulgent reported full year 2025 revenue of approximately $322.7 million, which was slightly below the updated guidance previously provided [2]. - The company also indicated a sequential decline in revenue for the fourth quarter [2]. Legal Investigation - The investigation by Lowey Dannenberg focuses on potential corporate fraud and malfeasance that may have led to financial losses for investors [1][4].